Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MORAb-003 Found Effective for Ovarian Cancer in PIIa Study: Eisai
June 16, 2008
- Kissei Licenses Selective SGLT-2 Inhibitors to GSK
June 16, 2008
- Incretin Therapy Highlighted at Annual Meeting of Japan Diabetes Society
June 16, 2008
- DSP Mounts Attack on Market for Antihypertensives with 7 Products with Different MOA
June 16, 2008
- 44th Annual Meeting of ASCO
June 16, 2008
- EPS to Embark on Chinese Business in Earnest
June 16, 2008
- R&D NEWS IN BRIEF
June 16, 2008
- CRO Business Pulls CMIC with 19.6% Increase in Sales
June 16, 2008
- TOPICS／27 Ex-Korosho Officials Employed by 17 Drug Makers
June 16, 2008
- BUSINESS NEWS IN BRIEF
June 16, 2008
- Banyu to Develop More Vaccines in Japan: New President Timney
June 16, 2008
- 3 Major Generics Makers Aim at Conservative Sales Targets for OTC Version of Amlodipine
June 16, 2008
- 34 Companies to Enter Market for Amlodipine with 70 Generic Products
June 16, 2008
- Source of Raw Materials of Generics Should Be Disclosed: JMA
June 16, 2008
- 5 Products with Expected Sales of Over \10 Bil. to Be Listed
June 16, 2008
- Industry Needs New Drug Pricing System: Mr Shoda
June 16, 2008
- Further Increase Use of Generics: Fiscal System Council
June 16, 2008
- REGULATORY NEWS IN BRIEF
June 16, 2008
- Changing Paradigm for Sales and Marketing Growing Markets for High- and Low-priced Drugs -1-
June 16, 2008
- NEW PRODUCT／Daiichi Sankyo: Gracevit Tablets 50 mg, Fine Granules 10%
June 16, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…